Campos‐Cabrera 2018.

Study characteristics
Methods	Trial acronym: none reported Design: randomised study with active control Median duration of follow‐up: not reported
Participants	Patients with multiple myeloma who received thalidomide‐ and dexamethasone‐based triplet induction therapy, maintenance with thalidomide and creatinine clearance > 30 mL/minute and had an additional cardiovascular risk factor. Median age: 67.5 years in rivaroxaban group; 66.8 years in aspirin group Gender, n (%) males: 3 (60%) males in rivaroxaban group; 10 (55.6%) males in aspirin group Metastatic disease: not reported Previous VTE: not reported
Interventions	Intervention 1: rivaroxaban 10 mg once daily Intervention 2: aspirin 100 mg once daily Treatment was continued until relapse and need another treatment
Outcomes	VTE including symptomatic or incidental DVT and symptomatic PE; bleeding
Notes	Funding: none reported Disclosure of potential conflicts of interest: "no relevant conflicts to declare." Publication format: published as conference abstract
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method of random sequence generation not reported.
Allocation concealment (selection bias)	Unclear risk	Method of allocation concealment not reported.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Method of blinding not reported.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Not clear if all participants included were analysed.
Selective reporting (reporting bias)	Unclear risk	Not clear if all outcomes were reported.